Regeneron Pharmaceuticals Inc. (REGN)

NASDAQ: REGN · USD

—

영어 원본으로 대체KO

번역하는 동안 영어 원본을 표시 중

이 리포트는 아직 번역되지 않았습니다. 번역 대기열이 따라잡으면 몇 분 후에 새로고침하세요.

StockMarketAgent Research · Analyzed 2026-05-10

Our latest published analysis: REGN rated Strong Buy

Regeneron Pharmaceuticals Inc.'s published Strong Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$1,210 / share

Potential value

$1,505 / share

Upside to FV

+69.2%

Moat

9/10

Wide

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$74.9B
P/E (forward)	13.3x

Market data

Price

Recent price action with selectable time range.

Financial snapshot

P/E (forward): 13.3x
Market cap: $74.9B

Item	P1	P2	P3	P4	P5	Trend
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	—	$12.17B	$13.12B	$14.20B	$14.34B	+5.6%
Gross profit	—	$10.61B	$11.30B	$12.23B	$12.24B	+4.9%
Operating income	—	$4.92B	$4.27B	$4.84B	$5.27B	+2.4%
Net income	—	$4.34B	$3.95B	$4.41B	$4.50B	+1.3%
EPS (diluted)	$71.97	$38.22	$34.77	$38.34	$41.48	-12.9%
EBITDA	—	$5.26B	$4.69B	$5.32B	$5.82B	+3.4%
R&D	—	$3.85B	$4.63B	$5.23B	$5.85B	+15.0%
SG&A	—	$2.12B	$2.63B	$2.95B	$2.70B	+8.5%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
AAPL	Apple Inc.	—	—	—	—	—	—	매도
ABNB	Airbnb, Inc.	—	—	—	—	—	—	매도
ADBE	Adobe Inc.	—	—	—	—	—	—	적극 매수
ABBV	AbbVie Inc.	—	—	—	—	—	—	매도
ABT	Abbott Laboratories	—	—	—	—	—	—	비중 축소
ALGN	Align Technology Inc.	—	—	—	—	—	—	비중 축소

Base and Bull scenarios

Bull20%

Price target

$1,505.07

+110.5% from spot

Dupixent dominates the immunology space longer than anticipated, and high-dose Eylea proves impenetrable to biosimilar erosion. Operating leverage drives margins past 35%, yielding an intrinsic value of $1,505.

Dupixent extends dominance in multi-indication immunology.
High-dose Eylea seamlessly defends franchise against biosimilars.
Operating margins expand beyond 35% on operating leverage.

Base60%

Price target

$1,209.72

+69.2% from spot

Our baseline assumes a successful transition from legacy assets to next-gen indications. Margins normalize to 30% as peak R&D spending subsides, anchoring fair value at $1,210 and bridging the gap from overly pessimistic internal valuation cross-checks.

Steady Dupixent growth offsets gradual Eylea base erosion.
R&D spend normalizes, returning operating margins to 30%.
Terminal growth rate of 3% with a terminal multiple of 18x.

Sensitivity: Ke × terminal growth

Ke ↓ / g →	2.0%	2.5%	3.0%	3.5%	4.0%
5.6%	$1,545	$1,793	$2,117	$2,117	$2,117
6.6%	$1,210	$1,357	$1,545	$1,793	$2,117
7.6%	$994	$1,091	$1,210	$1,357	$1,545
8.6%	$844	$913	$994	$1,091	$1,210
9.6%	$733	$784	$844	$913	$994

Scorecard

Published factor rows and weighted composite

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Forward P/E13.3

P25 n/aP50 n/aP75 n/a

Trailing P/E17.5

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROICn/a

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

Deeper analysis on REGN

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Quote this valuation with its source: Fair value, Potential value and the price at analysis.

Frequently asked questions

About this REGN report

What is the latest published REGN stock rating?

Regeneron Pharmaceuticals Inc. is shown with Strong Buy in the latest published report, analyzed 2026-05-10. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full REGN analysis?

The full latest published report, analyzed 2026-05-10, lives at /stocks/REGN/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for REGN?

The latest published report analyzed 2026-05-10 gives REGN a fair value of USD 1,210 and a potential value of USD 1,505. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the REGN page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-05-10). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

Strong BuyREGN · Fair value $1,210+69.2%

Read full analysis →

Category	Score	Reading
Valuation	9.5
Management	6.9
Balance Sheet	8.5
Profitability	6.5
Revenue Growth	7.5
Risk Assessment	9.0
Competitive Moat	9.0
Earnings Quality	6.0
Capital Efficiency	6.5

Regeneron Pharmaceuticals Inc. (REGN)

Our latest published analysis: REGN rated Strong Buy

Price

Financial snapshot

Fair-value bridge

Latest news · REGN

Valuation

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

Deeper analysis on REGN

Frequently asked questions

등급 이력